Yuyao Sun, Michael Benatar, Javier Mascías Cadavid, Dave Ennist, Paul Wicks, Kim Staats, Morgan Beauchamp, Sartaj Jhooty, Gary Pattee, Andrew Brown, Tulio Bertorini, Paul Barkhaus, Mark Bromberg, Greg Carter, Richard Bedlack, Xiaoyan Li
Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA...
July 26, 2023: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration